welcome to the OptumRx Drug store understandings podcast in this online forum we'' ll discuss the most recent and most impactful occasions in Drug store Advantage Administration with an emphasis on the emerging Solutions needed to control costs as well as make certain top quality of care I'' m your host Scott Draeger [Music] today I'' m signed up with by Mike einshofer Principal Pharmacy police officer at OptumRx Mike can you show to us a bit about your expert history and also specifically what a chief Drug store policeman is in charge of oh certain many thanks Scott and thanks for having me today so I'' ve remained in medical care about 25 years uh so a pharmacist you understand throughout a great deal of various elements within the sector I started as a retail pharmacist dealing with a large chain down in in Winston-Salem North Carolina after graduating from the University of Pittsburgh pharmacy college um after a couple of years of doing that I chose I wanted to go back to finish college so I sought a service level I appeared and benefited a health and wellness system or actually a local healthcare facility for an amount of time and so my first truly 6 years of my career were in straight Drug store method in retail as well as Healthcare facility setups uh I then began work within a Health insurance plan called UPMC Health insurance in Western Pennsylvania which was a wonderful experience over a variety of years I invested there which is where I actually started to find out how wellness insurance benefits work I began to actually begin to understand Specialty Drug store and began my occupation after concerning 6 years at UPMC at Walgreens Specialized Pharmacy which was just one of the biggest specialty pharmacies in the nation invested a number of years at Walgreens Specialty Pharmacy in a leadership duty a variety of years afterwards at a at a private equity-backed mid-tier healthcare services firm and afterwards about a year ago I joined Optimus the principal Pharmacy policeman so what does the primary Drug store police officer do uh well I'' m exceptionally happy with the job that all of our 15 000 Facility Pharmacists and various other medical professionals across the Venture do it to promote Drug store both coverage as well as look after our people we we cover about 60 million plus lives within the USA throughout several line of work consisting of business Medicare Medicaid and after that we have a huge section of our of our company which is what we call Business these are mainly employers local municipalities unions all teams that you know concerned us to aid them supply a pharmacy advantage to their employees and also their beneficiaries my task is to aid all of those components whether it'' s Medicare Medicaid however specifically the the business strategy sponsors to understand the kinds of Drug store programs that are available and what would function best for their members treatment Micah as you recall at your profession 25 plus years in the market what do you view as the the most significant changes uh within the occupation given that since you first began oh wow you recognize it'' s very different currently when I when I began a great deal of the drugs were type of mainstream Medical care illness medications right you if if you'' ve been around enough time you remember the purple tablet right you remember Lipitor the these were drugs that treated you know esophageal reflux disease as well as high cholesterol right as well as they were you know they have really you know direct marketed consumers or commercials and also they treated you know illness that impacted you understand a big swath of the population those diseases sanctuary'' t gone'away but what ' s occurred is in in in the last you recognize decade or so for all the you recognize for most of key bring illness excuse me if possibly diabetes mellitus as a tiny exception which still has some brand drugs a whole lot of the medications in this classification have actually gone generic and become you know much far more budget friendly than when they were branded but that'' s exactly how the system ' s made to work right pharmaceutical producers have a home window of time where they can be the sole manufacturer of the medicine in the United States and after that after that time several producers come right into the marketplace the patent no much longer uses as well as you see you see the cost typically drop precipitously over time as even more makers enter the marketplace so the largest point I see different Scott is that you have a lot of the health care diseases like high cholesterol and also esophageal reflux disease you see those medications currently really really affordable for most clients however you see specialty drugs ideal drugs that deal with very rare conditions like cystic fibrosis those didn'' t exist 20 some years earlier as well as now they are the fastest expanding section of Pharmacy and this develops a couple of of adjustments leading it'' s an enormous Renovation to The Human Problem the these drugs are dealing with problems currently that otherwise were you recognize had an incredible quantity of of Anguish or even a lot more fatal in a lot of cases uh Means Method Beyond a regular life-span currently they end up being persistent conditions and also so that'' s a great Testament to the scientific research behind all these growths but they also treat little populaces and are as a result extremely costly therefore the huge adjustment here is exactly how do the advantages type of develop to ensure that participants that in people that need these high cost treatments can afford them right since the you recognize a whole lot of these are biologic and a great deal of them are fairly new to the marketplace which indicates you recognize you won'' t have that kind of competition that'' ll that ' ll come years down the roadway and so we need to ensure that the advantages are designed in a method that strategies can manage them you recognize within their advantages and participants can afford them you understand when they need accessibility to them at an early stage you talk you also spoke about you recognize a treatment of persistent conditions and also how the industry has progressed with the induction of an increasing number of generic medicines are exist generics readily available for specialty medications and does that aid type of blunt these high rates that customers are seeing yep they'' re available absolutely is Scott and also so the main illness is in in specialty you know it'' s it ' s oncology or cancer it ' s cystic fibrosis it'' s rheumatoid joint inflammation'it ' s multiple sclerosis and after that there ' s lots of other very unusual genetic diseases you recognize that have truly truly tiny person populations typically the the ones I just walk through the ones which you recognize the top four cancer cells CF rheumatoid arthritis several sclerosis they all have generics in them as well as inflam in and also there'' s various other inflammatory problems besides rheumatoid like psoriasis and also psoriatic joint inflammation which all type of obtain lumped together in a general classification of inflammatory diseases they all have some variation of generics um I'' d say the largest development imminent and the one that doesn ' t have generics is rheumatoid arthritis which'' s since that category is mostly biologic in nature which indicates it'' s not a regular drug that treats us a lot a lot of the medicines in in the inflammatory area are injectable and they'' re really complex molecules that are made by not off a you understand off a conveyor belt but they'' re made in these huge bioreactors right that really make use of an organic system to produce the medication therefore traditional common kind of both from Governing and also for making factor of view that it'' s various as well as so in in the biologic room you have what'' s called biosimilars biosimilars in the United States began to emerge a number of years ago a lot of the medications nevertheless to date get on the clinical side so they'' re instilled items beginning in February of next year it'' ll be a large event since the globe ' s biggest drug which is deals with inflammatory conditions like psoriasis as well as rheumatoid joint inflammation and Crohn'' s a medication called Humira will begin to encounter biosimilar competition and this is a really essential growth for the entire sector since it'' ll now introduce direct competitors for Humira and you called we recognize and also as we'' ve seen across you recognize not simply in the biosumal room however simply in you recognize in basic competition you recognize increases as even more rivals go into the industry prices tend to decrease over time and we'' re really positive that as that biosimilar market for human wrestlers to create early following year that we'' ll beginning to see some much needed expense competitors arising within the inflammatory space Mike you mentioned rheumatoid arthritis and also specifically Humira for our listeners can you give some context what would certainly a typical set today spend for a prescription of Humira well I put on'' t I put on ' t intend to maybe highlight any one specific medicine but however as a whole specialized medicines can vary anywhere from a few thousand dollars to upwards of a hundred thousand dollars or even more per prescription the average specialty people around you recognize you can both work at around fifty thousand bucks a year yet again there'' s some you recognize that can extend right into the Millions so Mike how do customers afford these drugs that'' s a fantastic concern and you recognize this is among one of the most hotly sort of discussed topics that you see in the political circles today and also it'' s an actually really actually essential topic I desire to invest time on we really require to concentrate on how healthy and balanced is the insurance policy advantage layouts within our the industry that all of us get involved in right not simply the expense of the medication a great deal of the research out there supports you know over 3 billion dollars for a true unique brand-new treatment to make it to the industry so the solution isn'' t simply well the drugs should be economical since then you'' d have no innovation in the market where we have to look is just how do we gain access to budget friendly programs for participants and also individuals that require these medications you understand if you have a 10 thousand dollar drug right which is roughly the price of an oral oncology a dental cancer cells drug if it'' s 10 thousand bucks and you reduced the price by eighty percent right it'' s still not budget friendly to most U.S people therefore again back to the response we have to look Beyond simply the drug expense and also yes you recognize pbms awaken daily to hold manufacturers responsible for cost of the drugs they offer the industry that'' s among the major jobs that we do and also we do an actually great work at it however at the same time we have to locate Solutions within the coverage side and shield patients uh you understand from what we call Economic toxicity so they can get the medications that they need make you you describe a few of the challenges from the person perspective what about the payer point of view the clients that you that you talk to day after day you know what kind of strategies are available to those entities and as well as what do they need to think concerning um or what should they think about when adopting these methods yeah that'' s an excellent inquiry so first is not also regarding specialized the the first point I I speak with an employer around is what'' s their non-specialty coverage appearance like because what we find Scott is most employers that we speak to are concerned concerning specialized because you understand it'' s grown eight times greater than the non-specialty side over the past 13 years the typical side of of medicine costs has risen largely in in line with rising cost of living specifically expenses have actually climbed considerably more than that concerning Eightfold higher so of course and currently it'' s about 50 of the of the employer invest is on specialized medicines yet once again as I claimed earlier that 50 is coming from one to two percent of the populace so companies are truly a little worried around what'' s the long-term view on being able to pay for the this type of advantage uh as well as as well as the solution is very first look at your non-specialty side because we still see companies that will cover particular medications you know acne creams that cost thousands of bucks each right which have the exact same components in alternate formulas that are you understand extremely really extremely inexpensive like down in you know down in the 10 20 30 range so leading is allow'' s deal with every one of what we take into consideration to be the the waste within the advantage today and that liberates some extra funds that is after that they'' re after that available for the extra costly treatments then when you check out specialized it'' s looking into the long term and also you have to keep 2 things in mind you understand one is we intend to ensure that every patient that has a clinical requirement for one of these medicines has access to it to do that and keep it inexpensive for the company we have to locate affordability Solutions number one of course is a medical requirement process right into onto itself identifying that not all Physicians method versus the very same ideal practices as well as and and you recognize within the clinical literature as well as FDA approvals to make sure that'' s where the prior off procedure enters into area just to see to it that individuals that are recommended these high price treatments wouldn'' t be better matched with a different or perhaps no treatment whatsoever in the instance that sometimes we find a a major drug communication that makes the treatment that physician intends to recommended simply not clinically proper for the patient'' s particular individual circumstance the the third point is to check out points like how do we find other affordability Solutions uh that reduced the overall cost via the benefit layout you intend to have a capability to you'' ll hear the term refund tossed about ideal and also essentially all our refund is it stands for the pbm'' s ability to speak to a maker and have the manufacturer supply a discount rate for that certain medication when it'' s authorized for a client this is what drives considerable affordability for our strategy enrollers due to the fact that lacking that solution manufacturers would be able to bill whatever they want in the industry there'' d be really little control over the medical necessity demands to access a specific treatment as well as prices would certainly climb substantially as a result of both of those points since once again makers would certainly not have type of this checks and equilibriums procedure that pbms have in the marketplace that need them to not just show proof of just how their product is mosting likely to function yet also negotiate with us on the cost in exchange for their placement within our formulary if two medications are offered in the industry and also they both are clinically doing the exact same point we will certainly negotiate with each producer to primary develop a relationship with the one that we really feel is one of the most most affordable choice for most people always knowing Scott that there'' s an exception process that exists when a person can ' t gain from the drug that profits one of the most that'' s why we have a really durable exemptions procedure we take very seriously to make certain that those private clients demands are fit likewise so Mike I I truly enjoyed our discussion thanks significantly for spending a long time with us today oh thanks Scott international [Songs] many thanks for paying attention to the drug store understandings podcast tune in once again for even more discussions on the most crucial concerns in Pharmacy care services [Songs]
